Peritoneal (Abdominal Mesothelioma)
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy
Cancer Biology & Medicine 2024 November 1 [Link] Heliang Wu, Yi Wang, Yulin Lin, Ru Ma, Xuemei Du, Yandong Su, Rui Yang, Zhiran Yang, Xinli Liang, Yinguang Zhang, Xiaoqing Liang, Zhonghe Ji Chunning Lai, Yajing Huang, Yan Li Abstract Objective: Malignant peritoneal mesothelioma (MPM) is a rare primary malignant tumor with an extremely poor prognosis…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 2024 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 2024 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read MoreAntigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma
Scientific Reports 2024 October 29 [Link] Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M Dragovic Abstract Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of…
Read MoreAntigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma
Scientific Reports 2024 October 29 [Link] Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M Dragovic Abstract Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma. Intracavitary administration of…
Read MoreSystemic Therapy Options for Peritoneal Mesothelioma
Journal of the Comprehensive Cancer Network 2024 October [Link] Tawee Tanvetyanon, George R Simon Abstract Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials…
Read MoreGender- and Age-Based Characterization and Comparison of the Murine Primary Peritoneal Mesothelial Cell Proteome
bioRxiv 2024 October 11 [Link] Zhikun Wang, Yueying Liu, Reihaneh Safavisohi, Marwa Asem, Daniel D Hu, Mary Sharon Stack, Matthew M Champion Abstract Organs in the abdominal cavity are covered by a peritoneal membrane, which is comprised of a monolayer of mesothelial cells (MC). Diseases involving the peritoneal membrane include peritonitis, primary cancer (mesothelioma), and…
Read MoreChallenging the Norm: Occurrence of Synchronous Pleural and Peritoneal Mesothelioma in a Female Patient
Cureus 2024 August 18 [Link] Surendar Reddy, Kavya M G, Rakesh Gattu, Alekya P, Manasa Kuthadi Abstract Here, we present a unique case involving a female patient in her 40s with synchronous malignant pleural and peritoneal mesothelioma, despite lacking a history of asbestos exposure. The patient’s initial symptoms included dyspnoea, chest pain, cough, fever, appetite…
Read MoreThe Significance of the Morphological Appearance of Peritoneal Lesions on Imaging in Patients With Peritoneal Malignancies-A Report From Phase 1 of the PRECINCT Study
Journal of Surgical Oncology 2024 September 19 [Link] Aditi Bhatt, Pascal Rousset, Brendan J Moran, Mudaddal Kazi, Dario Baratti, Amine Souadka, Marcello Deraco, Paolo Sammartino, Armando Sardi, Olivier Glehen Abstract Peritoneal tumour dissemination is still considered as a terminal disease. For the last two decades, cytoreductive surgery (CRS) combined with intraoperative hyperthermic chemotherapy (HIPEC) has…
Read MorePerfusion Strategies for Cytoreductive Surgery With Heated Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Journal of Surgical Oncology 2024 September 10 [Link] Claire Drigotas, Alexander W Loftus, John B Ammori, Luke D Rothermel, Richard S Hoehn Abstract Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has been shown to improve survival for patients with malignant peritoneal mesothelioma (MPM). Presently, there is no standardized HIPEC protocol with respect to…
Read More
Skip to content